Use of Holter functions of the implantable pacemaker to control antiarrhythmic therapy of supraventricular and ventricular recurrent tachycardias
Language English Country Czech Republic Media print
Document type Comparative Study, Journal Article
PubMed
3234007
Knihovny.cz E-resources
- MeSH
- Anti-Arrhythmia Agents administration & dosage MeSH
- Electrocardiography instrumentation MeSH
- Atrial Flutter diagnosis drug therapy MeSH
- Pacemaker, Artificial * MeSH
- Humans MeSH
- Microcomputers * MeSH
- Monitoring, Physiologic instrumentation MeSH
- Follow-Up Studies MeSH
- Signal Processing, Computer-Assisted MeSH
- Heart Ventricles drug effects MeSH
- Tachycardia diagnosis drug therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
- Names of Substances
- Anti-Arrhythmia Agents MeSH
Holter functions of pacemakers were studied in a total of nine patients with paroxysmal atrial flutter (Group I--a Quintech DD 931 pacemaker, manufactured by Vitatron Medical, The Netherlands), and in 11 patients with recurrent postinfarction ventricular tachycardia (Group II--a DPG P 21 diagnostic pulse generator, Vitatron Medical. Seven patients (35%) were excluded from the study for myopotential interference. Group I patients were given six antiarrhythmic drugs for eight weeks each, with only prajmalin and amiodarone significantly shortening flutter duration. Group II patients were administered, according to the results of programmed extrastimulation, amiodarone alone or in combination with Class I antiarrhythmic drugs for a long period of time. While no recurrent tachycardias or sudden death were noted during treatment, pacemaker detected non-lethal ventricular tachycardia occurred in two, and sudden death without confirmed arrhythmia in one patient once the treatment had been discontinued for serious side effects (p less than 0.05). Diagnostic stimulation using bipelar sensing to eliminate myopotential interference might become a major method for long-term monitoring.